Active Biotech

ImmunicumBiotechnologySweden

70% match

Immunicum AB is a Swedish biotechnology company that developed allogeneic cell-based cancer immunotherapies, including the investigational product ilixadencel. Its programs were aimed at stimulating patients’ immune systems to treat solid tumors, serving oncology patients and healthcare providers.

Arctic Bioscience is a Norwegian biotech company that develops marine-derived health products and pharmaceutical candidates, particularly based on bioactive compounds from herring roe. It serves consumers and healthcare markets with omega-3 products and investigates treatments for inflammatory and autoimmune conditions.

ImmunOs Therapeutics AGBiotechnologySwitzerland

69% match

ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.

ONCOPEPTIDES0RN4 · BiotechUnited Kingdom

69% matchPublic

Oncopeptides is a pharmaceutical company that develops targeted cancer therapies utilizing proprietary platforms like peptide drug conjugates. The company focuses on treating difficult-to-treat hematological diseases and rare cancers, such as multiple myeloma, aiming to provide new treatment options for patients with significant unmet medical needs.

BioInvent International0H22 · BiotechSweden

69% matchPublic

Founded in 1996 and based in Lund, Sweden, BioInvent International AB (publ) is a clinical-stage biotechnology company dedicated to the discovery, research, and development of immuno-modulatory antibodies for cancer treatment. Its operations span Sweden, Europe, the United States, Japan, and other global regions. The company's leading therapeutic candidate, BI-1206, is under development for non-Hodgkin lymphoma and various solid tumors. BioInvent's pipeline also features projects targeting tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system. Other notable developments include BT-001 for solid tumors, and the anti-TNFR2 antibodies BI-1808 and BI-1910, intended for solid tumors and cutaneous T-cell lymphoma. BioInvent maintains strategic alliances, including a collaboration with Pfizer Inc. for antibodies against tumor-associated myeloid cells, and a co-development partnership with Transgene focused on multi-functional oncolytic viruses for solid tumors. Additionally, the company has a collaboration and supply agreement with Merck for the clinical progression of BI-1808.

Affimed Therapeutics is a biotechnology company focused on developing cancer immunotherapies that recruit and activate innate immune cells, particularly natural killer (NK) cells, to attack tumor cells. Its investigational products are intended for oncology patients and are developed for use by cancer-care providers.